Lexicon Pharma

$4.64 0.00% ($0.00)
  • 1D
  • 1W
  • 1M
  • 1Y
  • 5Y
  • YTD

Get ready to invest

Subscribe

About Lexicon Pharma

Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company. The Company focuses on the development and commercialization of treatments for human disease. The Company's drug programs include Sotagliflozin and LX9211. The Company also has a number of additional compounds into various stages of clinical and preclinical development. The Company’s LX9211 is an orally-delivered small molecule compound that is being developed for the treatment of neuropathic pain. The Company intends to initiate a Phase IIa clinical trial evaluating the safety and tolerability of LX9211 and its effects on diabetic peripheral neuropathic (DPN) pain. Its Sotagliflozin is an orally-delivered small molecule compound that is being developed for the treatment of type I diabetes and type II diabetes, heart failure and chronic kidney disease.

Stock Analysis

last close $4.74
1-mo return 9.5%
3-mo return -31%
avg daily vol. 595.1T
52-week high 9.65
52-week low 1.03
market cap. $703M
forward pe -
annual div. -
roe -12.5%
ltg forecast -
dividend yield -
annual rev. $16M
inst own. 85.2%
baraka

Subscribe now for daily local and international financial news

Subscribe